Updates

August 10, 2020August 10, 2020
FDA Will Review Two New Applications Seeking Keytruda Approval for TNBC

The U.S. Food and Drug Administration (FDA) has accepted to review two new Merck applications requesting the approval of Keytruda (pembrolizumab) for the treatment ... Read more
August 3, 2020August 3, 2020
Fewer, Higher Doses of Radiation Therapy Safe for Early Breast Cancer

For people with early breast cancer, delivering radiation therapy in fewer, larger doses does not increase the risk of long-term side effects from ... Read more
July 23, 2020July 23, 2020
Devyser’s Gene Screening Test for Breast, Ovarian Cancers Approved in Europe

Devyser’s hereditary breast and ovarian cancer (HBOC) test has received a CE mark from the European Commission and is now approved as a diagnostic test for both cancers ... Read more
July 20, 2020July 20, 2020
EU Certifies Software That Assesses Short-term Breast Cancer Risk

ProFound AI Risk, a diagnostic tool that estimates the risk of breast cancer over a two-year period following a mammogram, has received a CE mark from ... Read more
July 16, 2020July 16, 2020
Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows

Immunomedics has announced that its Phase 3 ASCENT trial of Trodelvy (sacituzumab govitecan) met its main goal of demonstrating that the medication is superior ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

June 22, 2018June 22, 2018

Clinical Trial of Tamoxifen-based Gel in Reducing Breast Density Recruiting in US, EU

News

The ability of a gel containing a tamoxifen-byproduct to reduce breast density — associated with an increased risk of breast cancer — is now being evaluated in a recruiting Phase 3 clinical trial. Approximately half of women in ... Read more

FDA Will Review Two New Applications Seeking Keytruda Approval for TNBC

Fewer, Higher Doses of Radiation Therapy Safe for Early Breast Cancer

Devyser’s Gene Screening Test for Breast, Ovarian Cancers Approved in Europe

EU Certifies Software That Assesses Short-term Breast Cancer Risk

Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows

Diet Rich in Fiber Linked to Lower Breast Cancer Risk, Pooled Data Show

EMA Grants Trastuzumab Deruxtecan Accelerated Assessment for Advanced HER2-positive Breast Cancer

Tecentriq-Chemo Combo Ups Percentage of TNBC Patients With No Cancer at Surgery

FDA Approves Phesgo as Injection Treatment for HER2-positive Breast Cancers

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

Cancer Vaccine Combo to be Tested in Triple Negative Breast Cancer

Subscribe to our mailing list

Pre-Surgical Imfinzi Combo Increases Cancer Eradication Chances in Trial

Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says

Merck to Launch Ontruzant, a Herceptin Biosimilar, in US

Kisqali Prolongs Overall Survival in Advanced Breast Cancer Patients with Internal Organ Metastases

3 Levels of Care Recommended for Breast Cancer Patients During COVID-19 Pandemic

Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say

Tukysa Approved as Combo Therapy for Metastatic HER2-positive Breast Cancer in Switzerland

FDA Approves Tukysa for Advanced HER2-positive Breast Cancer

Enhertu Approved for HER2-Positive Inoperable or Metastatic Cancer in Japan

Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

Concure’s New $2.5M Funding to Boost Patient Access to its Radioactive Seed Treatment

Positive Results Support Early Halt to Phase 3 Trial Testing Sacituzumab Govitecan for TNBC

CytoDyn Seeks Preliminary FDA Meeting on Leronlimab’s Breakthrough Therapy Status

Tumor Suppressor Neurofibromin Interacts with Estrogen Receptor, Revealing Potential Combo Breast Cancer Therapy

Komen Suggests Delaying Routine Mammograms During COVID-19 Outbreak

Herzuma, Biosimilar to Herceptin, Available in US for HER2-positive Breast Cancers

Fewer False-positive Mammograms May Need Human-Computer Mix

Tumor Mutations May Help Predict Patients Best Suited to Pre-surgery Chemotherapy

Platinum Chemo No Better than Standard in BRCA-mutated Early BC, Trial Finds

Certain Inhaled Anesthetics May Promote Breast Cancer Spread, Mouse Study Suggests

Lesser-known DNA Repair Process May Be Therapeutic Target in Certain Breast Cancers, Study Says

Breast Cancer Cells Precisely Mapped; Study Notes Potential for Individualized Treatment

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

Novel 3D Model Provides Early Insights on Breast Cancer Spread

FDA Approves Nerlynx-Capecitabine Combo for HER2-positive Metastatic Breast Cancer

New Formulation of Roche’s Perjeta-Herceptin Combo for HER2-Positive Breast Cancer Up for Possible FDA Approval

Magseed Approval Extended in Europe for Soft Tissues, Long-Term Implantation

Adding Keytruda to Chemo Slows Worsening in Advanced TNBC with PD-L1 Markers, Trial Finds

Tucatinib Granted FDA Priority Review for Advanced HER2-positive Breast Cancer

Pin It on Pinterest